()
 
 

Overview


Progenics Pharmaceuticals, Inc., of Tarrytown, NY, is a biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. Principal programs are directed toward gastroenterology as well as the treatment of HIV infection and cancer. The Company, in collaboration with Wyeth, is developing methylnaltrexone for the treatment of opioid-induced side effects, including constipation (oral and subcutaneous formulations) and post-operative bowel ileus (intravenous formulation). In March 2007, the Company submitted a New Drug Application to the United States Food and Drug Administration for the subcutaneous formulation of methylnaltrexone for patients suffering from opioid-induced constipation while receiving palliative care. In the area of HIV infection, the Company is developing the viral-entry inhibitor ...


Contact Information

777 Old Saw Mill River Road
Tarrytown, NY 10591

tel: 914-789-2800
fax: 914-789-2817
http://www.progenics.com

,  



Investor Relations



tel:
fax:




Stock

Exchange: NASDAQ
Industry: Drug Manufacturers - Other
Market Cap: $420.5M




 
The information provided here has been obtained from publicly available sources as well as directly from issuers in some cases. Please see our Disclaimer and Terms of Service for more information.